Skip to content

The Long-term Neurodevelopmental Outcome After Intraventricular Hemorrhage (IVH)-Grades I-II in Preterm Infants at Ages 1-7 Years

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01912703
Enrollment
700
Registered
2013-07-31
Start date
2013-12-31
Completion date
2014-12-31
Last updated
2013-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Infants

Brief summary

It is well-known that preterm delivery can be accompanied by complications. One of these complications is Intraventricular Hemorrhage (IVH). There are four degrees of IVH, according to severity. It is known that IVH Grades 3-4 can cause severe neurodevelopmental outcomes, including cerebral palsy (CP), hemiplegia, lower motor and cognitive skills and social difficulties. It is not known whether IVH Grades I-II have any of these effects and the aim of this study is to determine whether they do have any neurodevelopmental outcomes.

Interventions

OTHERTelephone interview

Subjects with incomplete data will be asked to complete a telephone interview

Sponsors

Hillel Yaffe Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 7 Years
Healthy volunteers
No

Inclusion criteria

* All preterm infants born at 35 weeks or less * Underwent at least 1 brain ultrasound * Diagnosed with IVH Grades 1-2 * Had no other severe illness in NICU * Had neurodevelopmental follow-up

Exclusion criteria

* All others

Design outcomes

Primary

MeasureTime frameDescription
General Neurodevelopmental AssessmentSeven yearsRetrospective study of preterm infants born in the years 2007-2011 and suffered IVH Grades 1-2 who have undergone a general neurodevelopmental assessment in the Institute for Child Development in Hillel Yaffe Medical Center at ages 1-7. This assessment will indicate whether IVH Grades 1-2 has any neurodevelopmental effect on these children.

Countries

Israel

Contacts

Primary ContactRoei Abramovitch, MD
roeiabra@gmail.com972-50-3205548

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026